Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals (NASDAQ:TTPH) from a sell rating to a hold rating in a research report report published on Friday morning.
According to Zacks, “Tetraphase Pharmaceuticals, Inc. is a life science company engaged in developing and commercializing tetracycline based drugs to treat drug-resistant infectious diseases, inflammation, and cancer. Its principal products include eravacycline, an intravenous and oral antibiotic for the treatment of multi-drug resistant Gram-negative infections. The Company’s product under development includes eravacycline oral formulation, TP-834 and TP-271. Tetraphase Pharmaceuticals, Inc. is based in Watertown, Massachusetts. “
Several other brokerages also recently commented on TTPH. HC Wainwright raised their target price on shares of Tetraphase Pharmaceuticals from $15.00 to $17.00 and gave the stock a buy rating in a report on Monday, November 6th. ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a sell rating to a strong sell rating in a report on Friday, December 1st. BMO Capital Markets lifted their price objective on shares of Tetraphase Pharmaceuticals from $13.00 to $24.00 and gave the company an outperform rating in a report on Wednesday, October 4th. Finally, Needham & Company LLC reiterated a hold rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, September 17th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Hold and a consensus target price of $15.15.
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) traded down $0.01 during mid-day trading on Friday, reaching $6.51. 286,743 shares of the company’s stock traded hands, compared to its average volume of 559,685. The firm has a market cap of $334.71, a P/E ratio of -2.27 and a beta of 2.51. Tetraphase Pharmaceuticals has a 52-week low of $3.57 and a 52-week high of $9.93.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.63) EPS for the quarter, hitting the consensus estimate of ($0.63). The firm had revenue of $4.10 million for the quarter, compared to the consensus estimate of $1.59 million. Tetraphase Pharmaceuticals had a negative net margin of 1,382.33% and a negative return on equity of 88.27%. The business’s quarterly revenue was up 355.6% on a year-over-year basis. During the same period last year, the company posted ($0.58) EPS. analysts forecast that Tetraphase Pharmaceuticals will post -2.88 earnings per share for the current year.
In other Tetraphase Pharmaceuticals news, Director L Patrick Gage acquired 3,880 shares of the stock in a transaction dated Wednesday, November 29th. The shares were bought at an average cost of $6.45 per share, for a total transaction of $25,026.00. Following the completion of the acquisition, the director now directly owns 38,880 shares of the company’s stock, valued at $250,776. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $6.03, for a total transaction of $52,762.50. Following the completion of the sale, the insider now owns 8,750 shares in the company, valued at $52,762.50. The disclosure for this sale can be found here. 5.50% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Tetraphase Pharmaceuticals in the third quarter valued at approximately $107,000. Brighton Jones LLC bought a new position in shares of Tetraphase Pharmaceuticals in the third quarter valued at $108,000. AXA bought a new position in shares of Tetraphase Pharmaceuticals in the second quarter valued at $132,000. Voya Investment Management LLC grew its stake in shares of Tetraphase Pharmaceuticals by 17.8% in the second quarter. Voya Investment Management LLC now owns 20,583 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 3,104 shares in the last quarter. Finally, Virtu KCG Holdings LLC bought a new position in shares of Tetraphase Pharmaceuticals in the second quarter valued at $147,000. Institutional investors own 58.15% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Tetraphase Pharmaceuticals (TTPH) Rating Increased to Hold at Zacks Investment Research” was first posted by Stock Observer and is owned by of Stock Observer. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.thestockobserver.com/2018/01/13/tetraphase-pharmaceuticals-ttph-rating-increased-to-hold-at-zacks-investment-research.html.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.